Inventor · disambiguated record
Bart S. Hendriks
Also filed as: HENDRIKS BART S
7 granted patents·15 pending applications·80 citations·filing 1999–2025
82Inventor score
Top patents by PatentIndex Score
22 records- 0192US9511155B2Compositions and methods for non-invasive imagingMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Dec 6, 2016·10 cites·19 claims
- 0290US11344552B2Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatinIPSEN BIOPHARM LTD·Filed 2017·Granted May 31, 2022·4 cites·15 claims
- 0383US2024358706A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinIPSEN BIOPHARM LTD·Filed 2024·Application pending·0 cites
- 0479US6548302B1Polymers for delivery of nucleic acidsUNIV JOHNS HOPKINS MED·Filed 1999·Granted Apr 15, 2003·64 cites·29 claims
- 0577US2025381191A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinIPSEN BIOPHARM LTD·Filed 2025·Application pending·0 cites
- 0675US2023062425A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinIPSEN BIOPHARM LTD·Filed 2022·Application pending·0 cites
- 0770US9226966B2Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 5, 2016·2 cites·10 claims
- 0866US2016067182A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0960US9968694B2Compositions and methods for non-invasive imagingMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted May 15, 2018·0 cites·20 claims
- 1059US2017231911A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1155US2016303264A1Liposomes useful for non-invasive imaging and drug deliveryMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1254US2017049775A1Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1352US2015111217A1Marker quantitation in single cells in tissue sectionsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 1452US2016184227A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1552US2017082630A1Marker quantitation in single cells in tissue sectionsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1650US9610249B2Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Apr 4, 2017·0 cites·22 claims
- 1749US2017189335A1Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1849US2017080087A1Combination Therapies for Treating Her2-Positive Cancers that are Resistant to Her2-Targeted TherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1945US2016038416A1Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2043US9913901B2Combination therapy for treating HER2-positive cancersMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Mar 13, 2018·0 cites·22 claims
- 2139US2017258903A1Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapiesMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 2237US2017022290A1Combination therapies for treating her2-positive cancersMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bart S. Hendriks files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →